Apellis Pharmaceuticals Announces Closing of Offering of Common Stock
April 23 2018 - 6:20PM
Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutic compounds to treat disease through the inhibition of
the complement system, today announced the closing of its
previously announced underwritten public offering of 5,500,000
shares of its common stock at a public offering price of $25.50 per
share. All of the shares in the offering were sold by Apellis. The
gross proceeds from the offering were approximately $140.3 million,
before deducting underwriting discounts and commissions and
expenses payable by Apellis.
Citigroup, J.P. Morgan and Cowen acted as joint book-running
managers for the offering.
A registration statement relating to the offering was filed with
the Securities and Exchange Commission and was declared effective
on April 18, 2018. This offering was made only by means of a
prospectus. Copies of the final prospectus relating to the offering
may be obtained by contacting: Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: 1-800-831-9146; J.P. Morgan Securities LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone: (866) 803-9204; or Cowen and
Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, telephone: (631) 274-2806.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Apellis
Apellis Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutic compounds for the treatment of a broad range of
life-threatening or debilitating autoimmune diseases based upon
complement immunotherapy through the inhibition of the complement
system at the level of C3. Apellis is the first company to advance
chronic therapy with a C3 inhibitor into clinical trials.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. The words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “will,” “would” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including the uncertainties related to market conditions
and the completion of the public offering on the anticipated terms
or at all, uncertainties inherent in the initiation of future
clinical trials and other factors discussed in the “Risk Factors”
section of the preliminary prospectus filed with the Securities and
Exchange Commission on April 16, 2018, Apellis’ Annual Report on
Form 10-K filed with the Securities and Exchange Commission on
March 19, 2018, and the risks described in other filings that
Apellis may make with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Apellis specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
Investor Contact:
Alex Kane
akane@w2ogroup.com
212.301.7218 (office)
929.400.2691 (mobile)
Media Contact:
Tully Nicholas
tnicholas@denterlein.com
617.482.0042 (office)
860.490.0218 (mobile)
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2023 to Apr 2024